title: Diagnosis and therapy of intrahepatic cholestasis of pregnancy.
abstract: Intrahepatic cholestasis of pregnancy (ICP) is characterized by the occurrence of pruritus mostly in the third trimenon. Diagnosis is based on the presence of pruritus and elevated levels of serum bile acids in the absence of pruritic skin diseases. There is strong evidence of a genetic predisposition for ICP. Numerous studies have investigated the association of known cholestasis genes such as ABCB4 (also designated MDR3), ABCB11 ( BSEP) and ATP8B1 ( FIC1) with ICP. The results of these studies implicate a heterogeneous etiology of this syndrome. ICP increases the risk of preterm delivery and fetal loss. Furthermore, intense pruritus may necessitate premature induction of labor with its known higher frequency of complications for mother and child. Therefore, ICP pregnancies should be managed as high-risk pregnancies. Pharmaceuticals to alleviate pruritus or improve cholestasis like antihistamines, phenobarbital, anion exchange resins, dexamethasone or S-adenosylmethionine are not widely accepted because of questionable efficacy or side effects. Recent randomized studies have shown beneficial effects of ursodeoxycholic acid (UDCA) on laboratory data and pruritus in patients with ICP. Improved knowledge about the diagnostic classification of different types and pathophysiological mechanisms of ICP may allow for a more targeted treatment of this disease in future.
authors.affiliation: Department of Internal Medicine I, University of Bonn, Germany.
authors.forename: T C
authors.initials: TC
authors.lastname: Paus
authors.forename: G
authors.initials: G
authors.lastname: Schneider
authors.forename: P
authors.initials: P
authors.lastname: Van De Vondel
authors.forename: T
authors.initials: T
authors.lastname: Sauerbruch
authors.forename: C
authors.initials: C
authors.lastname: Reichel
mesh_terms: D001647:Bile Acids and Salts / Q000097:blood; D002780:Cholestasis, Intrahepatic / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D002869:Chromosome Aberrations / Q000145:classification; D004252:DNA Mutational Analysis; D003937:Diagnosis, Differential; D005260:Female; D005808:Genes, Recessive / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D007231:Infant, Newborn; D007751:Labor, Induced; D007752:Obstetric Labor, Premature / Q000517:prevention & control; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis* / Q000188:drug therapy; D011263:Pregnancy Trimester, Third; D018566:Pregnancy, High-Risk / Q000235:genetics; D011537:Pruritus / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
chemical_list: D001647:Bile Acids and Salts; D014580:Ursodeoxycholic Acid